Durata Therapeutics Inc (NASDAQ:DRTX)

12.67
Data as of Apr 17
 -0.11 / -0.86%
Today’s Change
6.65
Today|||52-Week Range
16.99
-0.94%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$334.6M

Company Description

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its product candidate, dalbavancin, is in stage clinical development. The company is initially developing dalbavancin, an intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI, caused by Gram-positive bacteria, such as S. aureus, including Methicillin-Resistant and multi-drug resistant strains, and certain Streptococcal species. Dalbavancin is a second generation, semi-synthetic lipoglycopeptide designed for once-weekly intravenous dosing which will facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, reducing the length of a patient's hospital stay or avoiding hospital admission altogether and, ultimately, lowering the overall cost of care for these patients. The company was founded on November 4, 2009 and is headquartered in Chicago, IL.

Contact Information

Durata Therapeutics, Inc.
200 South Wacker Drive
Chicago Illinois 60606
P:(312) 219-7000
Investor Relations:

Employees

Shareholders

Mutual fund holders5.55%
Individual stakeholders45.26%
Other institutional25.66%

Top Executives

Paul R. EdickPresident, Chief Executive Officer & Director
Corey N. FishmanCOO, CFO, Secretary & Treasurer
Michael W. DunneChief Medical Officer
John Patrick ShannonChief Commercial Officer
Allison WeyVice President-Investor Relations & Public Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.